Baxter and ScinoPharm sign injectable oncology drug strategic alliance

Image: iStock/jarun011

Up to 20 injectable cancer drugs will be made at facilities in Taiwan and Germany under terms of a partnership between Baxter and Scinopharm.

Baxter International and ScinoPharm Taiwan announced a strategic partnership yesterday to develop, manufacture and commercialise an initial five oncology drugs, with scope for an additional 15 injectable molecules.

“The collaboration with ScinoPharm represents a rare and compelling opportunity to partner with one of the world’s leading active pharmaceutical ingredient [API] manufacturers with a 17-year history of quality and safety serving the global pharmaceutical industry,” a spokesperson from Baxter told in-Pharmatechnologist.com.

Current branded sales of the initial five products included in this partnership total more than $4bn annually. Baxter is not disclosing specific cost details associated with this partnership.”

Manufacturing

Manufacturing will be carried out at both Baxter’s facility in Halle, Germany and Scinopharm’s injectable plant in Tainan, Taiwan.

A Scinopharm spokesperson added the latter will be ready for registration batch production by 2017, with the first in-house ANDA submission from the partnership set for 2018, and a subsequent US FDA inspection approval expected in 2019.

“ScinoPharm will be responsible for raw material sourcing for all APIs and the injectables made in-house by ourselves,” Scinopharm told us. “Baxter will be responsible for raw material sourcing for the injectables made by themselves.”

Scinopharm invested NT$1.1bn ($36m) into its Tainan site in 2012 to build a high potency cytotoxic injectable plant, and as such does not need to add new capacity or staff to service this collaboration, we were told.

Related News

iStock/andrewsafonov

Connecticut ‘injects’ in SCA Pharma

iStock/scyther5

Baxter hires Indian contractor to expand injectables pipeline

iStock/Golden_Brown

Torbay Pharma opens plant with sterile injectables capacity in UK

Scinopharm hired to make API for skin infection antibiotic Baxdela

Scinopharm hired to make API for skin infection antibiotic Baxdela

iStock/Nostal6ie

ScinoPharm showcases water treatment tech at Baxdela API plant

Scinopharm site in Changshu , China will supplt Raffles with celecoxib  API

ScinoPharm to make API for Chinese drugmaker eyeing US celecoxib market

Scinopharm escapes Taiwan earthquake unscathed; API operations unaffected

Scinopharm escapes Taiwan earthquake unscathed; API operations unaffected

In 2016, ScinoPharm expects to launch six APIs in the US, Canada, and Australia. (Image: iStock)

ScinoPharm: expanding scope, more products in pipeline, says CEO

The tightening of GMP requirements in China should help ensure quality and reduce the overall number of API makers

China's GMP drive will reduce API competition, says ScinoPharm

Baxter ramps up Halle plant lyophilisation capacity, again

Baxter Evaluates Biomanufacturing at New Minnesota Plant

Baxter Evaluates Biomanufacturing at New Minnesota Plant

Related Products

See more related products